New study seeks best multiple myeloma treatment for seniors
NCT ID NCT03829371
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 22 times
Summary
This study compares standard treatments for multiple myeloma in people aged 65 and older who cannot have a stem cell transplant. It looks at two drug combinations, with or without daratumumab, to see which works best and how they affect quality of life. The goal is to find the best initial treatment for this group, considering both benefits and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Torino, TO, 10126, Italy
Conditions
Explore the condition pages connected to this study.